Clinical Trials Directory

Trials / Completed

CompletedNCT04224142

Evaluation of PKU Sphere in Maternal PKU

An Observational Study to Evaluate Metabolic Control and Dietary Management in Women With PKU Taking PKU Sphere During Pre-conception and/or Pregnancy

Status
Completed
Phase
Study type
Observational
Enrollment
12 (actual)
Sponsor
Vitaflo International, Ltd · Industry
Sex
Female
Age
16 Years
Healthy volunteers
Not accepted

Summary

This observational study aims to recruit females, aged 16 years and over, with phenylketonuria (PKU) or hyperphenylalaninemia (hyperphe) following dietary management advice pre-conception and/or during pregnancy, who are willing to take PKU sphere as part of their dietarty management.

Detailed description

The aim of this study is to observe dietary management and metabolic control in women taking PKU sphere pre-conceptually and/or during pregnancy. To do this the following data points will be captured: * Blood spot phenylalanine and tyrosine levels to measure metabolic control * Changes to dietary management and any adaptations arising from incorporating PKU Sphere * Compliance/adherence of patients to their recommended amount of protein substitute prescription. * Tolerance of PKU sphere with respect to gastrointestinal (GI) symptoms and pregnancy associated nausea and vomiting. * Acceptability of concurrent protein substitute(s) (if applicable). * Nutritional status and weight management. * Routine standard of care data on the final pregnancy outcome and postpartum.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTPKU spherePKU sphere is a Food for Special Medical Purposes (FSMP). This product is for use in the dietary management of phenylketonuria (PKU). It is a powdered, low phenylalanine medical food containing a balanced mix of GMP, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, and DHA. It is available in 27g sachets providing 15g PE and contains 28mg Phe and 35g sachets providing 20g PE and contains 36mg Phe.

Timeline

Start date
2019-07-29
Primary completion
2025-10-07
Completion
2025-10-07
First posted
2020-01-13
Last updated
2025-11-28

Locations

3 sites across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT04224142. Inclusion in this directory is not an endorsement.